SCHEMBL7125151

SCHEMBL7125151

COc1c(N)ccc(Nc2ccccc2)c1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.50
GAA P10253 10/20 0.50
ALDH1A1 P00352 9/20 0.50
KDM4E B2RXH2 6/20 0.50
MEN1 O00255 6/20 0.50
KMT2A Q03164 6/20 0.50
LMNA P02545 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2D6 P10635 1/20 0.50
HTT P42858 4/20 0.47
TDP1 Q9NUW8 3/20 0.47
THRB P10828 2/20 0.47
RECQL P46063 1/20 0.47
MMP14 P50281 1/20 0.47
RAB9A P51151 1/20 0.47
L3MBTL1 Q9Y468 4/20 0.45
MAPK1 P28482 3/20 0.45
GFER P55789 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7719696 0.74 GAA (0.68) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL2817959 0.74 GAA (0.63) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL4594726 0.74 ALDH1A1 (0.55) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL28366576 0.73 ALDH1A1 (0.46) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL30354998 0.73 RAB9A (0.60) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL31099173 0.73 RAB9A (0.60) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL5605050 0.72 MAPT (0.61) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL5605493 0.72 MAPT (0.61) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL2035899 0.72 GAA (0.55) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL11901473 0.71 KMT2A (0.38) MAPTGAAALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101328186-A Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER PROD INC (US) 2008-12-24 CN disclosed
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US disclosed
US-6492383-B1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2002-12-10 US disclosed
CN-1280580-A Thienopyrimidine and thienopyridine derivatives as anticancer agents PFIZER PROD INC (US) 2001-01-17 CN disclosed
EP-1028964-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2000-08-23 EP disclosed
WO-1999024440-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents TYMP, DPYD, HPRT1 MAPT 3791/4885GAA 3536/4885ALDH1A1 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.